aTyr Pharma (NASDAQ:ATYR – Get Free Report) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect aTyr Pharma to announce earnings of ($4.00) per share and revenue of $2.50 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.86) by $0.46. On average, analysts expect aTyr Pharma to post ($17.80) EPS for the current fiscal year and ($18.80) EPS for the next fiscal year.
aTyr Pharma Price Performance
NASDAQ:ATYR opened at $6.63 on Wednesday. The firm has a 50-day moving average of $12.65 and a 200-day moving average of $23.92. aTyr Pharma has a one year low of $4.07 and a one year high of $44.40.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a research report on Saturday. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.
Check Out Our Latest Analysis on aTyr Pharma
aTyr Pharma Company Profile
aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.
aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.
Read More
- Five stocks we like better than aTyr Pharma
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
